The diagnostic and molecular characteristics of malignant mesothelioma and ovarian/peritoneal serous carcinoma

Cytopathology

Volumn 22, Issue 1, 2011, Pages 5-21

  Davidson, B ^a,b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

Author keywords

Cancer biology; Cytology; Diagnosis; Effusion; Malignant mesothelioma; Serous carcinoma

Indexed keywords

ASBESTOS; CA 125 ANTIGEN; CALRETININ; CARBOPLATIN; CARCINOEMBRYONIC ANTIGEN; CD15 ANTIGEN; CD44V ANTIGEN; CISPLATIN; CYTOKERATIN 5; CYTOKERATIN 6; DESMIN; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPITHELIAL CELL ADHESION MOLECULE; EPITHELIAL MEMBRANE ANTIGEN; ESTROGEN RECEPTOR; GEMCITABINE; HYALURONIC ACID; MESOTHELIN; MITOMYCIN C; MONOCLONAL ANTIBODY B.72.3; MONOCLONAL ANTIBODY D2-40; NAVELBINE; PACLITAXEL; PEMETREXED; PODOPLANIN; RALTITREXED; THROMBOMODULIN; UNINDEXED DRUG; VIMENTIN;

ABDOMINAL HYSTERECTOMY; CANCER ADJUVANT THERAPY; CANCER STAGING; CANCER SURVIVAL; COMPARATIVE GENOMIC HYBRIDIZATION; CYTOPATHOLOGY; CYTOREDUCTIVE SURGERY; DIFFERENTIAL DIAGNOSIS; DOWN REGULATION; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; IMMUNOHISTOCHEMISTRY; OMENTECTOMY; OVARY CARCINOMA; PERITONEUM MESOTHELIOMA; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SALPINGOOOPHORECTOMY; TUMOR SUPPRESSOR GENE; UPREGULATION;

CARRIER PROTEINS; CLAUDINS; CYCLIN E; CYTODIAGNOSIS; DIAGNOSIS, DIFFERENTIAL; DNA-BINDING PROTEINS; EXUDATES AND TRANSUDATES; FEMALE; FOLATE RECEPTOR 1; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; INSULIN-LIKE GROWTH FACTOR II; MALE; MESOTHELIOMA; MUCIN-4; NEOPLASMS, CYSTIC, MUCINOUS, AND SEROUS; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; PREDICTIVE VALUE OF TESTS; TENASCIN; TUMOR MARKERS, BIOLOGICAL;

EID: 78651261767     PISSN: 09565507     EISSN: 13652303     Source Type: Journal    
DOI: 10.1111/j.1365-2303.2010.00829.x     Document Type: Review

References (154)

1. Britton M. The epidemiology of mesothelioma. Semin Oncol 2002;29:18-25.
2. Pass HI, Carbone M, Chahinian AP. Malignant mesothelioma. In: Cancer medicine, 7th edn. Kufe DW, Bast RC Jr, Hait WM et al. (eds). Hamilton: BC Decker Inc; 2006: pp. 1225-36.
3. Parker C, Neville E. Lung cancer. 8: management of malignant mesothelioma. Thorax 2003;58:809-13.
4. Spirtas R, Connelly RR, Tucker MA. Survival patterns for malignant mesothelioma: the SEER experience. Int J Cancer 1998;41:525-30.
5. Yang H, Testa JR, Carbone M. Mesothelioma epidemiology, carcinogenesis, and pathogenesis. Curr Treat Options Oncol 2008;9:147-57.
6. Centers for Disease Control and Prevention (CDC). Malignant mesothelioma mortality-United States, 1999-2005. MMWR Morb Mortal Wkly Rep 2009;58:393-6.
7. Hughes RS. Malignant pleural mesothelioma. Am J Med Sci 2005;329:29-44.
8. Robinson BW, Lake RA. Advances in malignant mesothelioma. N Engl J Med 2005;353:1591-603.
9. La Vecchia C, Decarli A, Peto J et al. An age, period and cohort analysis of pleural cancer mortality in Europe. Eur J Cancer Prev 2000;9:179-84.
10. Peto J, Decarli A, La Vecchia C, Levi F, Negri E. The European mesothelioma epidemic. Br J Cancer 1999;79:666-72.
11. Zervos MD, Bizekis C, Pass HI. Malignant mesothelioma 2008. Curr Opin Pulm Med 2008;14:303-9.
12. Stahel RA, Felley-Bosco E, Opitz I, Weder W. Malignant pleural mesothelioma. Future Oncol 2009;5:391-402.
13. López-Ríos F, Illei PB, Rusch V, Ladanyi M. Evidence against a role for SV40 infection in human mesotheliomas and high risk of false-positive PCR results owing to presence of SV40 sequences in common laboratory plasmids. Lancet 2004;364:1157-66.
14. Hesdorffer ME, Chabot J, DeRosa C, Taub R. Peritoneal mesothelioma. Curr Treat Options Oncol 2008;9:180-90.
15. Ray M, Kindler HL. Malignant pleural mesothelioma: an update on biomarkers and treatment. Chest 2009;136:888-96.
16. Rusch VW. A proposed new international TNM staging system for malignant pleural mesothelioma from the International Mesothelioma Interest Group. Lung Cancer 1996;14:1-12.
17. van Ruth S, Baas P, Zoetmulder FAN. Surgical treatment of malignant pleural mesothelioma. Chest 2003;123:551-61.
18. Burgers JA, Damhuis RA. Prognostic factors in malignant mesothelioma. Lung Cancer 2004;45(Suppl 1):S49-54.
19. Maziak DE, Gagliardi A, Haynes AE et al. Surgical management of malignant pleural mesothelioma: a systematic review and evidence summary. Lung Cancer 2005;48:157-69.
20. Neragi-Miandoab S, Richards WG, Sugarbaker DJ. Morbidity, mortality, mean survival, and the impact of histology on survival after pleurectomy in 64 patients with malignant pleural mesothelioma. Int J Surg 2008;6:293-7.
21. Schipper PH, Nichols FC, Thomse KM et al. Malignant pleural mesothelioma: surgical management in 285 patients. Ann Thorac Surg 2008;85:257-64.
22. Bertino P, Carbone M, Pass H. Chemotherapy of malignant pleural mesothelioma. Expert Opin Pharmacother 2009;10:99-107.
23. Bridda A, Padoan I, Mencarelli R, Frego M. Peritoneal mesothelioma: a review. MedGenMed 2007;9:32.
24. Yan TD, Welch L, Black D, Sugarbaker PH. A systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for diffuse malignancy peritoneal mesothelioma. W Ann Oncol 2007;18:827-34.
25. American cancer society. Global cancer facts and figures 2007. Atlanta, GA: American Cancer Society, 2008.
26. Berek JS, Bast RC Jr. Ovarian cancer. In: Cancer medicine, 7th edn. Kufe DW, Bast RC Jr, Hait WM et al. (eds). Hamilton: BC Decker Inc; 2006: pp. 1543-68.
27. Jacob IJ, Shepherd JH, Oran DH et al. eds. Ovarian Cancer. Oxford: Oxford University Press, 2002.
28. Holschneider CH, Berek JS. Ovarian cancer: epidemiology, biology, and prognostic factors. Semin Surg Oncol 2000;19:3-10.
29. McLemore MR, Miaskowski C, Aouizerat BE, Chen LM, Dodd MJ. Epidemiological and genetic factors associated with ovarian cancer. Cancer Nurs 2009;32:281-8.
30. Hennessy BT, Coleman RL, Markman M. Ovarian cancer. Lancet 2009;374:1371-82.
31. Kurman RJ, Visvanathan K, Roden R, Wu TC, ShihIe M. Early detection and treatment of ovarian cancer: shifting from early stage to minimal volume of disease based on a new model of carcinogenesis. Am J Obstet Gynecol 2008;198:351-6.
32. Heintz AP, Odicino F, Maisonneuve P et al. Carcinoma of the ovary FIGO 6th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet 2006;95(Suppl 1):S161-92.
33. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-49.
34. Nossov V, Amneus M, Su F et al. The early detection of ovarian cancer: from traditional methods to proteomics. Can we really do better than serum CA-125?. Am J Obstet Gynecol 2008;199:215-23.
35. Weinberg LE, Rodriguez G, Hurteau JA. The role of neoadjuvant chemotherapy in treating advanced epithelial ovarian cancer. J Surg Oncol 2010;101:334-43.
36. Armstrong DK, Bundy B, Wenzel L et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006;354:34-43.
37. Rao G, Crispens M, Rothenberg ML. Intraperitoneal chemotherapy for ovarian cancer: overview and perspective. J Clin Oncol 2007;25:2867-72.
38. Campos SM, Ghosh S. A current review of targeted therapeutics for ovarian cancer. J Oncol 2010 2010;2010:149362.
39. Collinson F, Jayson G. New therapeutic agents in ovarian cancer. Curr Opin Obstet Gynecol 2009;21:44-53.
40. Soslow RA. Histologic subtypes of ovarian carcinoma: an overview. Int J Gynecol Pathol 2008;27:161-74.
41. Dubeau L. The cell of origin of ovarian epithelial tumours. Lancet Oncol 2008;9:1191-7.
42. Pentheroudakis G, Pavlidis N. Serous papillary peritoneal carcinoma: unknown primary tumour, ovarian cancer counterpart or a distinct entity? A systematic review Crit Rev Oncol Hematol 2010;75:27-42.
43. Carlson JW, Miron A, Jarboe EA et al. Serous tubal intraepithelial carcinoma: its potential role in primary peritoneal serous carcinoma and serous cancer prevention. J Clin Oncol 2008;26:4160-5.
44. Nissan A, Stojadinovic A, Garofalo A, Esquivel J, Piso P. Evidence-based medicine in the treatment of peritoneal carcinomatosis: Past, present, and future. J Surg Oncol 2009;100:335-44.
45. Baker PM, Clement PB, Young RH. Malignant peritoneal mesothelioma in women: a study of 75 cases with emphasis on their morphologic spectrum and differential diagnosis. Am J Clin Pathol 2005;123:724-37.
46. Husain AN, Colby TV, Ordóñez NG et al. Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med 2009;133:1317-31.
47. Addis B, Roche H. Problems in mesothelioma diagnosis. Histopathology 2009;54:55-68.
48. Aerts JG, Delahaye M, van der Kwast TH et al. The high post-test probability of a cytological examination renders further investigations to establish a diagnosis of epithelial malignant pleural mesothelioma redundant. Diagn Cytopathol 2006;34:523-7.
49. Bedrossian CWM. Malignant Effusions: A Multimodal Approach to Cytologic Diagnosis. New-York: Igaku-Shoin; 1994.
50. Reis-Filho JS, de Landér Schmitt FC. Fluorescence in situ hybridization, comparative genomic hybridization, and other molecular biology techniques in the analysis of effusions. Diagn Cytopathol 2005;33:294-9.
51. Davidson B, Dong HP, Holth A, Berner A, Risberg B. Flow cytometric immunophenotyping of cancer cells in effusion specimens: diagnostic and research applications. Diagn Cytopathol 2007;35:568-78.
52. Illei PB, Rusch VW, Zakowski MF, Ladanyi M. Homozygous deletion of CDKN2A and codeletion of the methylthioadenosine phosphorylase gene in the majority of pleural mesotheliomas. Clin Cancer Res 2003;9:2108-13.
53. Kim JY, Harvard C, You L et al. Stathmin is overexpressed in malignant mesothelioma. Anticancer Res 2007;27:39-44.
54. Nagel H, Schulten HJ, Gunawan B, Brinck U, Füzesi L. The potential value of comparative genomic hybridization analysis in effusion-and fine needle aspiration cytology. Mod Pathol 2002;15:818-25.
55. Winter MJ, Nagtegaal ID, van Krieken JHJM, Litvinov SV. The epithelial cell adhesion molecule (Ep-CAM) as a morphoregulatory molecule is a tool in surgical pathology. Am J Pathol 2003;163:2139-48.
56. Delahaye M, van der Ham F, van der Kwast TH. Complementary value of five carcinoma markers for the diagnosis of malignant mesothelioma, adenocarcinoma metastasis, and reactive mesothelium in serous effusions. Diagn Cytopathol 1997;17:115-20.
57. Motherby H, Kube M, Friedrichs N et al. Immunocytochemistry and DNA-image cytometry in diagnostic effusion cytology I. Prevalence of markers in tumour cell positive and negative smears. Anal Cell Pathol 1999;19:7-20.
58. Maguire B, Whitaker D, Carrello S, Spagnolo D. Monoclonal antibody Ber-EP4: its use in the differential diagnosis of malignant mesothelioma and carcinoma in cell blocks of malignant effusions and FNA specimens. Diagn Cytopathol 1994;10:130-4.
59. Davidson B, Risberg B, Kristensen G et al. Detection of cancer cells in effusions from patients diagnosed with gynaecological malignancies. Evaluation of five epithelial markers. Virchows Arch 1999;435:43-9.
60. Davidson B, Nielsen S, Christensen J et al. The role of Desmin and N-cadherin in effusion cytology: a comparative study using established markers of mesothelial and epithelial cells. Am J Surg Pathol 2001;25:1405-12.
61. Yuan Y, Nymoen DA, Tuft Stavnes H et al. Tenascin-X is a novel diagnostic marker of malignant mesothelioma. Am J Surg Pathol 2009;33:1673-82.
62. Thor A, Gorstein F, Ohuchi N et al. Tumor-associated glycoprotein (TAG-72) in ovarian carcinomas defined by monoclonal antibody B72.3. J Natl Cancer Inst 1986;76:995-1006.
63. Ordóñez NG. Value of immunohistochemistry in distinguishing peritoneal mesothelioma from serous carcinoma of the ovary and peritoneum: a review and update. Adv Anat Pathol 2006;13:16-25.
64. Riera JR, Astengo-Osuna C, Longmate JA, Battifora H. The immunohistochemical diagnostic panel for epithelial mesothelioma. A reevaluation after heat-induced epitope retrieval. Am J Surg Pathol 1997;21:1409-19.
65. Sheibani K, Battifora H, Burke JS, Rappaport H. Leu-M1 antigen in human neoplasms. An immunohistologic study of 400 cases. Am J Surg Pathol 1986;10:227-36.
66. Zhu W, Michael CW. WT1, monoclonal CEA, TTF1, and CA125 antibodies in the differential diagnosis of lung, breast, and ovarian adenocarcinomas in serous effusions. Diagn Cytopathol 2007;35:370-5.
67. Duffy MJ, Sturgeon C, Lamerz R et al. Tumor markers in pancreatic cancer: a European Group on Tumor Markers (EGTM) status report. Ann Oncol 2010;21:441-7.
68. Fetsch PA, Abati A, Hijazi YM. Utility of the antibodies CA 19-9, HBME-1, and thrombomodulin in the diagnosis of malignant mesothelioma and adenocarcinoma in cytology. Cancer 1998;84:101-8.
69. Menard S, Castronovo V, Tagliabue E, Sobel ME. New insights into the metastasis-associated 67 kD laminin receptor. J Cell Biochem 1997;67:155-65.
70. Menard S, Tagliabue E, Colnaghi MI. The 67 kDa laminin receptor as a prognostic factor in human cancer. Breast Cancer Res Treat 1998;52:137-45.
71. Reich R, Vintman L, Nielsen S et al. Differential expression of the 67 kilodalton laminin receptor in malignant mesothelioma and carcinomas that spread to serosal cavities. Diagn Cytopathol 2005;33:332-7.
72. Rogers JH. Calretinin: a gene for a novel calcium-binding protein expressed principally in neurons. J Cell Biol 1987;105:1343-53.
73. Wieczorek TJ, Krane JF. Diagnostic utility of calretinin immunohistochemistry in cytologic cell block preparations. Cancer 2000;90:312-9.
74. Miettinen M, Kovatich AJ. HBME-1-a monoclonal antibody useful in the differential diagnosis of mesothelioma, adenocarcinoma, and soft tissue and bone tumors. Appl Immunohistochem 1995;3:115-22.
75. Ascoli V, Carnovale-Scalzo C, Taccogna S, Nardi F. Utility of HBME-1 immunostaining in serous effusions. Cytopathology 1997;8:328-35.
76. Wick MR, Hornick JL. Immunohistology of Soft Tissue and Osseous Neoplasms. In: Diagnostic Immunohistochemistry, 3rd edn. Dabbs DJ, (ed). Philadelphia PA: Saunders; 2010: p. 90.
77. Shen J, Pinkus GS, Deshpande V, Cibas ES. Usefulness of EMA, GLUT-1, and XIAP for the cytologic diagnosis of malignant mesothelioma in body cavity fluids. Am J Clin Pathol 2009;131:516-23.
78. Hasteh F, Lin GY, Weidner N, Michael CW. The use of immunohistochemistry to distinguish reactive mesothelial cells from malignant mesothelioma in cytologic effusions. Cancer Cytopathol 2010;118:90-6.
79. Lee SB, Haber DA. Wilms tumor and the WT1 gene. Exp Cell Res 2001;264:74-99.
80. Hecht JL, Lee BH, Pinkus JL, Pinkus GS. The value of Wilms tumor susceptibility gene 1 in cytologic preparations as a marker for malignant mesothelioma. Cancer 2002;96:105-9.
81. Kalof AN, Cooper K. D2-40 immunohistochemistry-so far. Adv Anat Pathol 2009;16:62-4.
82. Bassarova AV, Nesland JM, Davidson B. D2-40 is not a specific marker for cells of mesothelial origin in serous effusions. Am J Surg Pathol 2006;30:878-82.
83. Hanna A, Pang Y, Bedrossian CW, Dejmek A, Michael CW. Podoplanin is a useful marker for identifying mesothelioma in malignant effusions. Diagn Cytopathol 2010;38:264-9.
84. Dejmek A, Hjerpe A. The combination of CEA, EMA, and BerEp4 and hyaluronan analysis specifically identifies 79% of all histologically verified mesotheliomas causing an effusion. Diagn Cytopathol 2005;32:160-6.
85. Afify AM, Stern R, Michael CW. Differentiation of mesothelioma from adenocarcinoma in serous effusions: the role of hyaluronic acid and CD44 localization. Diagn Cytopathol 2005;32:145-50.
86. Sivertsen S, Berner A, Michael CW, Bedrossian C, Davidson B. Cadherin expression in ovarian carcinoma and malignant mesothelioma cell effusions. Acta Cytol 2006;50:603-7.
87. Ordóñez NG. Application of mesothelin immunostaining in tumor diagnosis. Am J Surg Pathol 2003;27:1418-28.
88. Sivertsen S, Hadar R, Elloul S et al. Expression of Snail, Slug and Sip1 in malignant mesothelioma effusions is associated with matrix metalloproteinase, but not with cadherin expression. Lung Cancer 2006;54:309-17.
89. Davidson B, Reich R, Berner A et al. Ovarian carcinoma cells in serous effusions show altered MMP-2 and TIMP-2 mRNA levels. Eur J Cancer 2001;37:2040-9.
90. Elloul S, Bukholt Elstrand M, Nesland JM et al. Snail, Slug, and Smad-interacting protein 1 as novel parameters of disease aggressiveness in metastatic ovarian and breast carcinoma. Cancer 2005;103:1631-43.
91. Davidson B, Reich R, Lazarovici P et al. Expression of the nerve growth factor receptors TrkA and p75 in malignant mesothelioma. Lung Cancer 2004;44:159-65.
92. Davidson B, Reich R, Lazarovici P et al. Expression and activation of the nerve growth factor receptor TrkA in serous ovarian carcinoma. Clin Cancer Res 2003;9:2248-59.
93. Sigstad E, Dong HP, Nielsen S et al. Quantitative analysis of integrin expression in effusions using flow cytometric immunophenotyping. Diagn Cytopathol 2005;33:321-31.
94. Davidson B, Vintman L, Zcharia E et al. Heparanase and basic fibroblast growth factor are co-expressed in malignant mesothelioma. Clin Exp Metastasis 2004;21:469-76.
95. Davidson B, Shafat I, Ilan N et al. Heparanase expression correlates with poor survival in metastatic ovarian carcinoma. Gynecol Oncol 2007;104:311-9.
96. Kleinberg L, Lie AK, Flørenes VA, Nesland JM, Davidson B. Expression of inhibitors of apoptosis (IAP) family members in malignant mesothelioma. Hum Pathol 2007;38:986-94.
97. Kleinberg L, Flørenes VA, Silins I et al. Nuclear expression of Survivin is associated with improved survival in metastatic ovarian carcinoma. Cancer 2007;109:228-38.
98. Davidson B, Zhang Z, Kleinberg L et al. Gene expression signatures differentiate ovarian/peritoneal serous carcinoma from diffuse malignant peritoneal mesothelioma. Clin Cancer Res 2006;12:5944-50.
99. Tsukita S, Furuse M, Itoh M. Multifunctional strands in tight junctions. Nat Rev Mol Cell Biol 2001;2:285-93.
100. González-Mariscal L, Betanzos A, Nava P, Jaramillo BE. Tight junction proteins. Prog Biophys Mol Biol 2003;81:1-44.
101. Van Itallie CM, Anderson JM. Claudins and epithelial paracellular transport. Annu Rev Physiol 2006;68:403-29.
102. Hewitt KJ, Agarwal R, Morin PJ. The claudin gene family: expression in normal and neoplastic tissues. BMC Cancer 2006;6:186.
103. Morin PJ. Claudin proteins in human cancer: promising new targets for diagnosis and therapy. Cancer Res 2005;65:9603-6.
104. Swisshelm K, Macek R, Kubbies M. Role of claudins in tumorigenesis. Adv Drug Deliv Rev 2005;57:919-28.
105. Huang YH, Bao Y, Peng W et al. Claudin-3 gene silencing with siRNA suppresses ovarian tumor growth and metastasis. Proc Natl Acad Sci U S A 2009;106:3426-30.
106. Agarwal R, D'Souza T, Morin PJ. Claudin-3 and claudin-4 expression in ovarian epithelial cells enhances invasion and is associated with increased matrix metalloproteinase-2 activity. Cancer Res 2005;65:7378-85.
107. Suzuki M, Kato-Nakano M, Kawamoto S et al. Therapeutic antitumor efficacy of monoclonal antibody against Claudin-4 for pancreatic and ovarian cancers. Cancer Sci 2009;100:1623-30.
108. Romani C, Comper F, Bandiera E et al. Development and characterization of a human single-chain antibody fragment against claudin-3: a novel therapeutic target in ovarian and uterine carcinomas. Am J Obstet Gynecol 2009;201:70.e1-9.
109. Yuan X, Lin X, Manorek G et al. Recombinant CPE fused to tumor necrosis factor targets human ovarian cancer cells expressing the claudin-3 and claudin-4 receptors. Mol Cancer Ther 2009;8:1906-15.
110. Kleinberg L, Holth A, Fridman E et al. The diagnostic role of claudins in serous effusions. Am J Clin Pathol 2007;127:928-37.
111. Facchetti F, Lonardi S, Gentili F et al. Claudin 4 identifies a wide spectrum of epithelial neoplasms and represents a very useful marker for carcinoma versus mesothelioma diagnosis in pleural and peritoneal biopsies and effusions. Virchows Arch 2007;451:669-80.
112. Kleinberg L, Holth A, Trope' CG, Reich R, Davidson B. Claudin upregulation in ovarian carcinoma effusions is associated with poor survival. Hum Pathol 2008;39:747-57.
113. Byrd JC, Bresalier RS. Mucins and mucin binding proteins in colorectal cancer. Cancer Metastasis Rev 2004;23:77-99.
114. Carraway KL III, Funes M, Workman HC, Sweeney C. Contribution of membrane mucins to tumor progression through modulation of cellular growth signaling pathways. Curr Top Dev Biol 2007;78:1-22.
115. Porchet N, Nguyen VC, Dufosse J et al. Molecular cloning and chromosomal localization of a novel human tracheo-bronchial mucin cDNA containing tandemly repeated sequences of 48 base pairs. Biochem Biophys Res Commun 1991;175:414-22.
116. Moniaux N, Nollet S, Porchet N et al. Complete sequence of the human mucin MUC4: a putative cell membrane-associated mucin. Biochem J 1999;338:325-33.
117. Moniaux N, Escande F, Batra SK et al. Alternative splicing generates a family of putative secreted and membrane-associated MUC4 mucins. Eur J Biochem 2000;267:4536-44.
118. Singh AP, Chaturvedi P, Batra SK. Emerging roles of MUC4 in cancer: a novel target for diagnosis and therapy. Cancer Res 2007;67:433-6.
119. Davidson B, Baekelandt M, Shih IeM. MUC4 is upregulated in ovarian carcinoma effusions and differentiates carcinoma cells from mesothelial cells. Diagn Cytopathol 2007;35:756-60.
120. Hwang HC, Clurman BE. Cyclin E in normal and neoplastic cell cycles. Oncogene 2005;24:2776-86.
121. Deshpande A, Sicinski P, Hinds PW. Cyclins and cdks in development and cancer: a perspective. Oncogene 2005;24:2909-15.
122. Nakayama K, Nakayama N, Jinawath N et al. Amplicon profiles in ovarian serous carcinomas. Int J Cancer 2007;120:2613-7.
123. Etemadmoghadam D, deFazio A, Beroukhim R et al. Integrated genome-wide DNA copy number and expression analysis identifies distinct mechanisms of primary chemoresistance in ovarian carcinomas. Clin Cancer Res 2009;15:1417-27.
124. Nakayama N, Nakayama K, Shamima Y et al. Gene amplification CCNE1 is related to poor survival and potential therapeutic target in ovarian cancer. Cancer 2010;116:2621-4.
125. Porter DC, Zhang N, Danes C et al. Tumor-specific proteolytic processing of cyclin E generates hyperactive lower-molecular-weight forms. Mol Cell Biol 2001;21:6254-69.
126. Davidson B, Skrede M, Silins I et al. Low molecular weight cyclin E forms differentiate ovarian carcinoma from cells of mesothelial origin and are associated with poor survival in ovarian carcinoma. Cancer 2007;110:1264-71.
127. Denley A, Cosgrove LJ, Booker GW, Wallace JC, Forbes BE. Molecular interactions of the IGF system. Cytokine Growth Factor Rev 2005;16:421-39.
128. Guvakova MA. Insulin-like growth factors control cell migration in health and disease. Int J Biochem Cell Biol 2007;39:890-909.
129. Sachdev D, Yee D. Disrupting insulin-like growth factor signaling as a potential cancer therapy. Mol Cancer Ther 2007;6:1-12.
130. Beauchamp MC, Yasmeen A, Knafo A, Gotlieb WH. Targeting insulin and insulin-like growth factor pathways in epithelial ovarian cancer. J Oncol 2010;2010: 257058.
131. Slipicevic A, Øy GF, Askildt IC et al. The diagnostic and prognostic role of the insulin growth factor pathway members IGF-II and IGFBP3 in serous effusions. Hum Pathol 2009;40:527-37.
132. Kelemen LE. The role of folate receptor α in cancer development, progression and treatment: Cause, consequence or innocent bystander? Int J Cancer 2006;119:243-50.
133. Salazar MD, Ratnam M. The folate receptor: What does it promise in tissue-targeted therapeutics? Cancer Metastasis Rev 2007;26:141-52.
134. Parker N, Turk MJ, Westrick E et al. Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay. Anal Biochem 2005;338:284-93.
135. Kalli KR, Oberg AL, Keeney GL et al. Folate receptor alpha as a tumor target in epithelial ovarian cancer. Gynecol Oncol 2008;108:619-26.
136. Hough CD, Cho KR, Zonderman AB, Schwartz DR, Morin PJ. Coordinately up-regulated genes in ovarian cancer. Cancer Res 2001;61:3869-76.
137. Yuan Y, Nymoen DA, Dong HP et al. Expression of the folate receptor genes FOLR1 and FOLR3 differentiates ovarian carcinoma from breast carcinoma and malignant mesothelioma in serous effusions. Hum Pathol 2009;40:1453-60.
138. Chiquet-Ehrismann R. Tenascins. Int J Biochem Cell Biol 2004;36:986-90.
139. Jones FS, Jones PL. The tenascin family of ECM glycoproteins: structure, function, and regulation during embryonic development and tissue remodeling. Dev Dyn 2000;218:235-59.
140. Orend G, Chiquet-Ehrismann R. Tenascin-C induced signaling in cancer. Cancer Lett 2006;244:143-63.
141. Orend G. Potential oncogenic action of tenascin-C in tumorigenesis. Int J Biochem Cell Biol 2005;37:1066-83.
142. Tucker RP, Chiquet-Ehrismann R. The regulation of tenascin expression by tissue microenvironments. Biochim Biophys Acta 2009;1793:888-92.
143. Bristow J, Carey W, Egging D, Schalkwijk J. Tenascin-X, collagen, elastin, and the Ehlers-Danlos syndrome. Am J Med Genet C Semin Med Genet 2005;139:24-30.
144. Wu C. The PINCH-ILK-parvin complexes: assembly, functions and regulation. Biochim Biophys Acta 2004;1692:55-62.
145. Hehlgans S, Haase M, Cordes N. Signalling via integrins: implications for cell survival and anticancer strategies. Biochim Biophys Acta 2007;1775:163-80.
146. Sun XF, Zhang H. Clinicopathological significance of stromal variables: angiogenesis, lymphangiogenesis, inflammatory infiltration, MMP and PINCH in colorectal carcinomas. Mol Cancer 2006;5:43.
147. Legate KR, Montañez E, Kudlacek O, Fässler R. ILK, PINCH and parvin: the tIPP of integrin signalling. Nat Rev Mol Cell Biol 2006;7:20-31.
148. Wang-Rodriguez J, Dreilinger AD, Alsharabi GM, Rearden A. The signaling adapter protein PINCH is upregulated in the stroma of common cancers, notably at invasion edges. Cancer 2002;95:1387-95.
149. Zhu Z, Yang Y, Zhang Y et al. PINCH expression and its significance in esophageal squamous cell carcinoma. Dis Markers 2008;25:75-80.
150. Gao J, Arbman G, Rearden A, Sun XF. Stromal staining for PINCH is an independent prognostic indicator in colorectal cancer. Neoplasia 2004;6:796-801.
151. Zhao ZR, Zhang ZY, Cui DS et al. Particularly interesting new cysteine-histidine rich protein expression in colorectal adenocarcinoma. World J Gastroenterol 2006;12:298-301.
152. Kim SK, Jang HR, Kim JH et al. The epigenetic silencing of LIMS2 in gastric cancer and its inhibitory effect on cell migration. Biochem Biophys Res Commun 2006;349:1032-40.
153. Yuan Y, Dong HP, Nymoen DA et al. PINCH-2 expression in cancers involving the serosal cavities. Cytopathology 2010. doi: [Epub ahead of print].
154. Davidson B, Tuft Stavnes H, Holth A et al. Gene expression signatures differentiate ovarian/peritoneal serous carcinoma from breast carcinoma in effusions. J Cell Mol Med 2010. doi: 10.1111/j.1582-4934.2010.01019.x [Epub ahead of print].